Arcus Biosciences Advances Gastrointestinal Cancer Treatment

Arcus Biosciences (RCUS) has provided an update.

Arcus Biosciences unveiled promising interim results from its Phase 2 EDGE-Gastric trial, assessing the efficacy of combining domvanalimab, zimberelimab, and chemotherapy in treating upper gastrointestinal cancers. The data revealed a median Progression-Free Survival of 12.9 months overall, with higher rates in PD-L1-high patients. The Objective Response Rate stood at 58.5%, demonstrating the treatment’s potential. Additionally, the safety profile was consistent with expectations, with the most common side effects being infusion-related reactions. These encouraging findings indicate a significant step forward in gastrointestinal cancer therapy.

Learn more about RCUS stock on TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.